Alzheimer-like Plaque Formation by Human Macrophages Is Reduced by Fibrillation Inhibitors and Lovastatin

Journal of Molecular Biology

Volumn 360, Issue 2, 2006, Pages 251-257

  Gellermann, Gerald P ^a   Ullrich, Kathrin ^a   Tannert, Astrid ^a   Unger, Christiane ^a   Habicht, Gernot ^b   Sauter, Simon R N ^c   Hortschansky, Peter ^b   Horn, Uwe ^b   Möllmann, Ute ^b   Decker, Michael ^d   Lehmann, Jochen ^d   Fändrich, Marcus ^a  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c BIOCONE   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

aggregation; drug screen; mononuclear phagocytes; prion; protein folding

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; ANTIFIBRINOLYTIC AGENT; APOLIPOPROTEIN E; CHOLESTEROL; CONGO RED; GLYCOSAMINOGLYCAN; MELANTONINE; MEVINOLIN; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; MACROPHAGE; MOLECULAR DYNAMICS; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION;

LYCHNIS CHALCEDONICA;

EID: 33745235789     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.05.026     Document Type: Article

References (34)

1. Westermark P., Benson M.D., Buxbaum J.N., Cohen A.S., Frangione B., Ikeda S., et al. Nomenclature Committee of the International Society of Amyloidosis. Amyloid: toward terminology clarification. Amyloid 12 (2005) 1-4
2. Kisilevsky R. Amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol. 130 (2000) 99-108
3. Gellermann G.P., Appel T.R., Tannert A., Radestock A., Hortschansky P., Schroeckh V., et al. Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl Acad. Sci. USA 102 (2005) 6297-6302
4. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today 5 (1999) 343-350
5. Gervais F., Chalifour R., Garceau D., Kong X., Laurin J., McLaughlin R., et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 8 (2001) 28-35
6. Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S., et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl Acad. Sci. USA 99 (2002) 16400-16406
7. Lewis H.D., Beher D., Smith D., Hewson L., Cookson N., Reynolds D.S., et al. Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. Neurobiol. Aging 9 (2004) 1175-1185
8. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
9. Nagele R.G., Wegiel J., Venkataraman V., Imaki H., Wang K.C., and Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 25 (2004) 663-674
10. Stalder M., Phinney A., Probst A., Sommer B., Staufenbiel M., and Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 154 (1999) 1673-1684
11. Chronopoulos S., Laird D.W., and Ali-Khan Z. Immunolocalization of serum amyloid A and AA amyloid in lysosomes in murine monocytoid cells: confocal and immunogold electron microscopic studies. J. Pathol. 173 (1994) 361-369
12. Hou F.F., and Owen Jr. W.F. Beta 2-microglobulin amyloidosis: role of monocytes/macrophages. Curr. Opin. Nephrol. Hypertens. 11 (2002) 417-421
13. Tagouri Y.M., Sanders P.W., Picken M.M., Siegal G.P., Kerby J.D., and Herrera G.A. In vitro AL-amyloid formation by rat and human mesangial cells. Lab. Invest. 74 (1996) 290-302
14. Muhleisen H., Gehrmann J., and Meyermann R. Reactive microglia in Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 21 (1995) 505-517
15. Chung H., Brazil M.I., Soe T.T., and Maxfield F.R. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J. Biol. Chem. 274 (1999) 32301-32308
16. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
17. Elimova E., Kisilevsky R., Szarek W.A., and Ancsin J.B. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J. 18 (2004) 1749-1751
18. Kluve-Beckerman B., Liepnieks J.J., Wang L., and Benson M.D. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am. J. Pathol. 155 (1999) 123-133
19. Yazawa H., Yu Z.X., Takeda K., Le Y., Gong W., Ferrans V.J., et al. Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 15 (2001) 2454-2462
20. Gueft B., and Ghidoni J.J. The site of formation and ultrastructure of amyloid. Am. J. Pathol. 43 (1963) 837-854
21. Braak H., Braak E., Ohm T., and Bohl J. Alzheimer's disease: mismatch between amyloid plaques and neuritic plaques. Neurosci. Letters 103 (1989) 24-28
22. Jin L.-W., Claborn K.A., Kurimoto M., Geday M.A., Maezawa I., Sohraby F., et al. Imaging linear birefringence and dichroism in cerebral amyloid pathologies. Proc. Natl Acad. Sci. USA 100 (2003) 15294-15298
23. Lindberg C., Hjorth E., Post C., Winblad B., and Schultzberg M. Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone. Neurotox. Res. 8 (2005) 267-276
24. Lee V.M. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol. Aging 23 (2002) 1039-1042
25. Aitken J.F., Loomes K.M., Konarkowska B., and Cooper G.J. Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem. J. 374 (2003) 779-784
26. Peterson S., Klabunde T., Lashuel H.A., Purkey H., Sacchettini J.C., and Kelly J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl Acad. Sci. USA 95 (1998) 12956-12960
27. Li G., Shofer J.B., Kukull W.A., Peskind E.R., Tsuang D.W., Breitner J.C., et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurolog. 65 (2005) 1045-1050
28. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
29. Shobab L.A., Hsiung G.Y., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 4 (2005) 841-852
30. Sparks D.L., Petanceska S., Sabbagh M., Connor D., Soares H., Adler C., et al. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr. Alzheimer Res. 2 (2005) 527-539
31. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell. Biol. 7 (2005) 1118-1123
32. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98 (2001) 5856-5861
33. Hortschansky P., Schroeckh V., Christopeit T., Zandomeneghi G., and Fändrich M. The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci. 7 (2005) 1753-1759
34. Wogulis M., Wright S., Cunningham D., Chilcote T., Powell K., and Rydel R.E. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci. 25 (2005) 1071-1080